Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming

Gene Therapy

Volumn 6, Issue 4, 1999, Pages 471-481

  Ohmoto, Y ^a,b,c   Wood, M J A ^b   Charlton, H M ^b   Kajiwara, K ^a,b   Perry, V H ^b   Wood, K J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenoviral vector; Brain; Environmental condition; Mouse strain; Priming; SPF

Indexed keywords

BETA GALACTOSIDASE; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL GENE; BRAIN CELL; CELL INFILTRATION; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENE TARGETING; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STRAIN DIFFERENCE; T LYMPHOCYTE; TRANSGENE;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SPECIFIC PATHOGEN-FREE ORGANISMS; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0032962974     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300851     Document Type: Article

References (71)

1. Simon RH et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther 1993; 4: 771-780.
2. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. j Virol 1995; 69: 2004-2015.
3. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses gene transfer. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
4. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E-1 deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
5. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
6. Byrnes AP et al. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015-1024.
7. Byrnes AP, Wood MJA, Charlton HM. Role of T cells in the inflammation caused by adenovirus vectors in the brain. Gene Therapy 1996; 3: 644-651.
8. Wood MJA et al. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 1996; 19: 497-501.
9. Kajiwara K et al. Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther 1997; 8: 253-265.
10. Korber B, Mermod N, Hood L, Stroynowski I. Regulation of gene expression by interferons: control of H-2 promoter responses. Science 1988; 239: 1302-1306.
11. Gribaudo G et al. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. Virology 1993; 197: 303-311.
12. Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995; 6: 1291-1297.
13. Qin L et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
14. Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
15. Knight V, Kasel JA. Viral and mycoplasmal infections of the respiratory tract. In: Knight V (ed). Adenoviruses. Lea and Febiger: Philadelphia, 1973, pp 65.
16. Williams KA, Hart DNJ, Fabre JW, Morris PJ. Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues. Transplantation 1980; 29: 274-279.
17. Hart DNJ, Fabre JW. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissue, but not brain. J Exp Med 1981; 154: 347-361.
18. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 1996; 74: 599-608.
19. Bell MD et al. Recombinant human adenovirus with rat MIP-2 gene insertion causes prolonged PMN recruitment to the murine brain. Eur J Neurosci 1996; 8: 1803-1811.
20. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
21. Akli S et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3: 224-228.
22. Davidson BL et al. A model system for in vivo gene transfer into the CNS using an adenoviral vector. Nat Genet 1993; 3: 219-223.
23. Geddes BJ, Harding TC, Lightman SL, Uney JB. Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Med 1997; 3: 1402-1404.
24. Horellou P, Sabaté O, Buc-Caron M-H, Mallet J. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease. Exp Neurol 1997; 144: 131-138.
25. Byrnes AP, Maclaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression and demyelination. J Neurosci 1996; 16: 3045-3055.
26. Stratford-Perricaudet LD et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
27. Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
28. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
29. Karougliak V, Graham FL. Development of cell lines capable of complementing E1, E4 and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6: 1575-1586.
30. Wang Q, Finer MH. Second-generation adenovirus vectors. Nature Med 1996; 2: 714-716.
31. Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Therapy 1997; 4: 393-400.
32. Schowalter DB et al. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. Gene Therapy 1997; 4: 853-860.
33. Qin L et al. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997; 8: 1365-1374.
34. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
35. Cichon G, Strauss M. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer. Gene Therapy 1998; 5: 85-90.
36. + T cell regulation during the induction phase of the response. Eur J Immunol 1995; 25: 2643-2649.
37. Guérette B et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996; 7: 1455-1463.
38. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy 1998; 5: 309-319.
39. Kägi D et al. Cytotoxic mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
40. + T cell. J Exp Med 1996; 184: 863-871.
41. Nash AA, Sunil-Chandra NP. Interactions of murine gammaherpesvirus with the immune system. Curr Opin Immunol 1994; 6: 560-563.
42. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992; 175: 1143-1145.
43. + T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994; 180: 1273-1282.
44. b gene. J Immunol 1995; 155: 2955-2959.
45. Stevenson PG, Hawke S, Sloan DJ, Brangham RM. The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 1997; 71: 145-151.
46. + CTLs in vivo. J Immunol 1995; 155: 2564-2570.
47. k. Immunogenetics 1978; 7: 551-561.
48. Ashman RB. Persistence of cell-mediated immunity to influenza A virus in mice. Immunology 1982; 47: 165-168.
49. Jamieson BD, Ahmed R. T cell memory. Long-term persistence of virus-specific cytotoxic T cells. J Exp Med 1989; 169: 1993-2005.
50. Madsen JC, Wood KJ, Morris PJ. Effects of anti-L3T4 and anti-LYT2 monoclonal antibody therapy on cardiac allograft survival in presensitized recipients. Transplant Proc 1989; 21: 1022.
51. Razvi ES, Welsh RM, Mcfarland HI. In vivo state of antiviral CTL precursors. J Immunol 1995; 154: 620-632.
52. Yang H, Welsh RM. Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol 1986; 136: 1186-1193.
53. Yang H, Dundon PL, Nahill SR, Welsh RM. Virus-indiced polyclonal cytotoxic T lymphocytes stimulation. J Immunol 1989; 142: 1710-1718.
54. Tough DF, Sprent J. Virus and T cell turnover: evidence for bystander proliferation. Immunol Rev 1996; 150: 129-142.
55. Lule J et al. The spontaneous development of immune complex type glomerular lesions in outbred mice is dependent on environmental factors and sex. J Clin Lab Immunol 1989; 29: 111-118.
56. Allansmith MR et al. The immune response of the lacrimal grand to antigenic exposure. Curr Eye Res 1987; 6: 921-927.
57. Gallimore A et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998; 187: 1383-1393.
58. McMichael AJ. T cell responses and viral escape. Cell 1998; 93: 673-676.
59. Barr D et al. Strain-related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
60. Demant P, Lipoldova M, Svobodova M. Resistance to Leishmania major in mice. Science 1996; 274: 1392-1393.
61. Gorham JD et al. Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc Natl Acad Sci USA 1996; 93: 12467-12472.
62. Rawle FC et al. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus type 5. J Immunol 1991; 146: 3977-3984.
63. Kaplan JM et al. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1997; 8: 45-56.
64. Alpers JH, Steward MW, Soothill JF. Differences in immune elimination in inbred mice. Clin Exp Immunol 1972; 12: 121-132.
65. Smith TAG et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
66. Juillard V et al. Long-term humoral and cellular immunity induced by a signal immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
67. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
68. Springer T, Galfè G, Secher DS, Milstein C. Monoclonal xenogenic antibodies to murine cell surface antigens: identification of novel leukocyte differentiation antigens. Eur J Immunol 1978; 8: 539-551.
69. Tomonari K. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 1988; 28: 455-458.
70. Qin S et al. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987; 17: 1159-1165.
71. Cobbold SP et al. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312: 548-551.